Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-5 Sub-study 1: Belantamab Mafodotin + GSK3174998 in RRMM
NCT06160609Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Primary endpoints: Dose Limiting Toxicities up to 21 days, Adverse Events up to 170 weeks and 3 more. Started Oct 2019; status: terminated.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06160609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160609.